Streetbeat News

Regulatory

CNET

ZW Data Action Technologies Inc. (NASDAQ:CNET) has received a non-compliance notice from Nasdaq due to its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024. The company requires additional time to prepare, review, and finalize its financial statements.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 8:01 pm

BURU

Nuburu will be issued US Patent Number 11,986,883 for its 'Blue Laser Metal Additive Manufacturing System (Using A Digital Mirror Device)' tomorrow.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 7:58 pm

SPY

Senate Majority Leader Chuck Schumer announced that a bipartisan border bill will be voted on Thursday.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 7:58 pm

TNL

Travel + Leisure Co has entered into amended and restated employment agreements with its President & CEO, Michael Brown, and CFO, Michael Hug, as per an SEC filing on May 17.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 7:55 pm

MT

VFS

The U.S. International Trade Commission (ITC) has initiated a patent investigation requested by ArcelorMittal concerning certain aluminum automotive products. This probe could impact companies involved in the production and distribution of these products.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 7:28 pm

BTCUSD

ETHUSD

Bloomberg reporters Eric Balchunas and James Seyffart have increased their odds of a spot Ether ETF approval to 75% from 25%, based on recent chatter suggesting the SEC might reverse its stance on this issue.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 7:27 pm

AMGN

AZN

Amgen and AstraZeneca announced results from the Phase 2a COURSE trial of Tezspire for severe COPD, showing mixed efficacy results. The drug showed a 17% reduction in COPD exacerbations overall, but more significant reductions in specific patient subgroups. The safety profile was consistent with its approved severe asthma indication.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:38 pm

ESPR

Esperion Therapeutics and Otsuka Pharmaceutical announced that their partnered cholesterol drug, bempedoic acid, achieved the primary endpoint in a Phase 3 trial in Japan. The trial showed statistically significant positive outcomes for patients with high LDL cholesterol. Otsuka plans to submit a New Drug Application in Japan in late 2024. Additionally, Esperion received a U.S. Patent Term Extension for bempedoic acid, extending its patent through December 2030. Following the news, Esperion's stock rose by 5.51%.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:22 pm

MDT

Medtronic's Sphere-9 catheter has demonstrated safety and efficacy in treating atrial fibrillation, outperforming the conventional Thermocool SmartTouch SF catheter in a clinical study. The results were presented at the Heart Rhythm Society 2024 Annual Meeting and published in Nature Medicine. The Sphere-9 catheter showed a favorable safety profile and superior procedural efficiency, leading to improved patient outcomes.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:22 pm

SPY

Federal Reserve's Mester has revised her expectations, stating that she no longer anticipates three rate cuts this year, which could impact market sentiment.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 6:13 pm